Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company’s management team will participate in the following upcoming investor conferences:
-
H.C. Wainwright 28th Annual Global Healthcare Conference, September 14-16, 2026
- Format: Fireside chat and one-on-one meetings
- Presentation Date & Time: September 14, 2026, 9:30 am ET
- Location: New York, NY and virtual
-
Baird’s 2026 Global Healthcare Conference, September 15, 2026
- Format: Company presentation and one-on-one meetings
- Presentation Date & Time: September 15, 2026, 9:40 am ET
- Location: New York, NY
-
TD Cowen’s 6th Annual Novel Mechanisms in Neuropsychiatry Summit, September 23, 2026
- Format: Fireside chat
- Presentation Date & Time: September 23, 2026, 3 pm ET
- Location: Virtual
The presentations will be accessible via a live webcast on the Events and Presentations page in the Investors section of Alto’s website and a replay will be available following the presentation.
About Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.
Availability of Information on Alto’s Website
Alto routinely uses its investor relations website to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website.
Investor Contact:
investors@altoneuroscience.com
Media Contact:
media@altoneuroscience.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260909519463/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States